Imprimis Pharmaceuticals reported a net loss of $5.7 million, or $0.28 per share, in the third quarter of 2017 compared with a net loss of $3.9 million, or $0.29 per share, in the third quarter of 2016, according to a company press release.
Total revenues for the quarter increased from $4.9 million to $6.5 million, while ophthalmology-related revenue was up 60% to $4.9 million.
General and administrative costs decreased from $5 million to $4.5 million for the quarter.
Uncategorized